Dana–Farber/Harvard Cancer Center (DF/HCC) unites the cancer research efforts of the Harvard community. It is an expansion of Dana–Farber Cancer Institute’s original designation as a Comprehensive Cancer Center in the early 1970s.

As a consortium, DF/HCC brings together more than 1,000 faculty members from of its seven Harvard–affiliated institutions: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana–Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital. Together, cancer researchers from these institutions receive more than $500 million annually in cancer–related grants.

The mission of DF/HCC is to speed the conversion of cancer research discoveries into improved prevention, diagnosis, and treatment. The research activities of the Center are organized and conducted through disease–specific and discipline–based research programs that cross both institutional and scientific boundaries. The Center supports 17 core facilities, and has implemented a fully integrated system for developing and performing clinical trials. Today, DF/HCC has one of the most robust cancer clinical trials programs in the country.

DF/HCC is committed to maximizing the impact of its research so that the cancer burden in all populations is reduced, and to eliminating disparities in minority and medically underserved groups.

For adults:
877-442-3324 (877-442-DFCI)

For children:
888-733-4662 (888-PEDI-ONC)

OR fill out an online application: https://www.dana-farber.org/apps/request-an-appointment.aspx

*Source: National Cancer Institute